Ingavirin syrup 30mg / 5ml, 90ml

Ingavirin syrup 30mg / 5ml, 90ml; 'Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in adults and children from 3 years of age.

Inside. Regardless of the meal.

Insert the measuring syringe firmly into the neck of the bottle. Turn the bottle upside down and gently pull the plunger down to draw the syrup up to the desired mark. After use, rinse the syringe in warm water and dry it.

For the treatment and prevention of influenza and acute respiratory viral infections, adults are prescribed 90 mg (15 ml) once a day, children from 7 years old - 60 mg (10 ml) once a day, children from 3 to 6 years old - 30 mg (5 ml) once a day. The duration of treatment for influenza and acute respiratory viral infections in adults and children from 7 years is 5-7 days (depending on the severity of the condition).

The duration of treatment for influenza and acute respiratory viral infections in children from 3 to 6 years is 5 days.

Taking the drug begins from the moment the first symptoms of the disease appear, preferably no later than 2 days from the onset of the disease.

Adults and children with severe symptoms, as well as in the presence of concomitant diseases (diseases of the respiratory and cardiovascular systems, diabetes mellitus, obesity), should take a double dose of the drug in the first 3 days of illness, then continue taking at the usual dosage for 2 -4 days.

For the prevention of influenza and acute respiratory viral infections after contact with sick persons, adults and children from 7 years old, the drug is prescribed for 7 days, for children from 3 to 6 years old, within 5 days.

If after 5 days of treatment there is no improvement or the symptoms worsen, or new symptoms appear, you should consult your doctor. Use the drug only according to the indications, the route of administration and the doses indicated in the instructions.

The syrup is in the form of a transparent, colorless, slightly viscous liquid with a characteristic odor.

5 ml

pentanedioic acid imidazolylethanamide (vitaglutam) 30 mg

Excipients: maltitol, glycerol, citric acid monohydrate, xanthan gum, sodium methyl parahydroxybenzoate, pear flavor, purified water.

• Hypersensitivity to the active substance or any other component of the drug.

• Sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.

• Pregnancy.

• Breastfeeding period.

• Children under 3 years old.

pharmachologic effect

Antiviral drug. Preclinical and clinical studies have shown efficacy against type A influenza viruses (A / H1N1, including 'swine' A / H1N1 pdm09, A / H3N2), A / H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, incl. Coxsackie virus and rhinovirus. Promotes accelerated elimination of viruses, shortening the duration of the disease, and reducing the risk of complications. The mechanism of action is realized at the level of infected cells by stimulating factors of innate immunity, suppressed by viral proteins. Experimental studies have shown, in particular,that IngavirinЃ increases the expression of the first type of interferon IFNAR receptor on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to signals from endogenous interferon. The process is accompanied by the activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It has been shown that under conditions of infection, the drug stimulates the production of the antiviral effector protein MxA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication. The drug causes an increase in the content of interferon in the blood to a physiological norm, stimulates and normalizes the reduced? -Interferon-producing ability of blood leukocytes,stimulates? -interferon-producing ability of leukocytes. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells, which have a high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells, which have a high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells, which have a high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.possessing high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.possessing high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.a decrease in the activity of myeloperoxidase. Experimental studies have shown that combined use with antibiotics increases the effectiveness of therapy on the model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug.

Pharmacokinetics

When used in recommended doses, the determination of the drug in blood plasma by available methods is not possible. In experimental studies using a radioactive label, it was found that the drug quickly enters the bloodstream from the gastrointestinal tract and is evenly distributed throughout the internal organs. Cmax in blood, blood plasma and most organs is reached 30 minutes after drug administration. The values ??of the AUC of the kidneys, liver and lungs slightly exceed the AUC of the blood (43.77 ?g ? h / g). The AUC values ??of the spleen, adrenal glands, lymph nodes and thymus are below the AUC of blood. The average retention time of the drug in the blood is 37.2 hours. With the course of taking the drug 1 time / day, it accumulates in the internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each injection of the drug were identical:a rapid increase in the concentration of the drug after each injection 0.5-1 hours after administration and then a slow decrease by 24 hours. It is not metabolized in the body and is excreted unchanged. The main process of elimination occurs within 24 hours. During this time, 80% of the dose taken is eliminated. During the first 5 hours, 34.8% is withdrawn, in the following hours - 45.2%. Of these, 77% are excreted through the intestines, 23% through the kidneys.

Side effect

Rarely: allergic reactions.

Drug interactions

Concomitant use of other antiviral drugs is not recommended.